BG63906B1 - Фармацевтичен аерозолен състав - Google Patents

Фармацевтичен аерозолен състав Download PDF

Info

Publication number: BG63906B1
Authority: BG; Bulgaria
Prior art keywords: composition; aerosol; volatile component; inhaler; low
Prior art date: 1997-06-13

Application number

BG103221A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG103221A (en

Inventor

David Lewis

Davis Ganderton

Brian Meakin

Paolo Ventura

Gaetano Brambilla

Raffaella Garzia

Original Assignee

Chiesi Farmaceutici S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-13

Filing date

1999-03-01

Publication date

2003-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG63906(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-03-01 Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.

1999-09-30 Publication of BG103221A publication Critical patent/BG103221A/xx

2003-06-30 Publication of BG63906B1 publication Critical patent/BG63906B1/bg

Links

239000000203 mixture Substances 0.000 title claims abstract description 117
239000008249 pharmaceutical aerosol Substances 0.000 title claims description 5
239000000443 aerosol Substances 0.000 claims abstract description 65
239000002245 particle Substances 0.000 claims abstract description 59
239000003380 propellant Substances 0.000 claims abstract description 39
239000013543 active substance Substances 0.000 claims abstract description 26
239000002904 solvent Substances 0.000 claims abstract description 18
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 56
238000009472 formulation Methods 0.000 claims description 32
150000005828 hydrofluoroalkanes Chemical class 0.000 claims description 32
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 14
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 14
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 14
239000005642 Oleic acid Substances 0.000 claims description 14
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 14
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 14
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 14
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 11
238000000034 method Methods 0.000 claims description 11
239000006184 cosolvent Substances 0.000 claims description 10
229950000210 beclometasone dipropionate Drugs 0.000 claims description 7
238000011049 filling Methods 0.000 claims description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 4
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
125000003158 alcohol group Chemical group 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 33
235000011187 glycerol Nutrition 0.000 description 17
239000000126 substance Substances 0.000 description 15
230000000694 effects Effects 0.000 description 13
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 10
230000008021 deposition Effects 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
210000004072 lung Anatomy 0.000 description 8
239000003814 drug Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 6
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 5
229940079593 drug Drugs 0.000 description 5
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000000654 additive Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000002270 dispersing agent Substances 0.000 description 4
230000005484 gravity Effects 0.000 description 4
229960001361 ipratropium bromide Drugs 0.000 description 4
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
235000015112 vegetable and seed oil Nutrition 0.000 description 3
239000008158 vegetable oil Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
-1 CFC compounds Chemical class 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229940071648 metered dose inhaler Drugs 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229940127557 pharmaceutical product Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000255789 Bombyx mori Species 0.000 description 1
208000027775 Bronchopulmonary disease Diseases 0.000 description 1
230000005653 Brownian motion process Effects 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000002590 anti-leukotriene effect Effects 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
238000003287 bathing Methods 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940124748 beta 2 agonist Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
238000005537 brownian motion Methods 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
150000001840 cholesterol esters Chemical class 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
229960005233 cineole Drugs 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000035876 healing Effects 0.000 description 1
UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
239000000832 lactitol Substances 0.000 description 1
235000010448 lactitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
229960003451 lactitol Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 1
229950010248 loretin Drugs 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229940038384 octadecane Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dispersion Chemistry (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG103221A 1997-06-13 1999-03-01 Фармацевтичен аерозолен състав BG63906B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9712434A GB2326334A (en)	1997-06-13	1997-06-13	Pharmaceutical aerosol compositions
PCT/EP1998/003533 WO1998056349A1 (en)	1997-06-13	1998-06-10	Pharmaceutical aerosol composition

Publications (2)

Publication Number	Publication Date
BG103221A BG103221A (en)	1999-09-30
BG63906B1 true BG63906B1 (bg)	2003-06-30

Family

ID=10814179

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103221A BG63906B1 (bg)	1997-06-13	1999-03-01	Фармацевтичен аерозолен състав

Country Status (44)

Country	Link
EP (2)	EP0920302B2 (hr)
JP (1)	JP4380802B2 (hr)
KR (1)	KR100546239B1 (hr)
CN (1)	CN1138532C (hr)
AR (1)	AR012977A1 (hr)
AT (1)	ATE222751T1 (hr)
AU (1)	AU729966B2 (hr)
BG (1)	BG63906B1 (hr)
BR (1)	BR9805993B1 (hr)
CA (1)	CA2263445C (hr)
CO (1)	CO4940408A1 (hr)
CZ (1)	CZ295521B6 (hr)
DE (1)	DE69807420T3 (hr)
DK (1)	DK0920302T4 (hr)
DZ (1)	DZ2516A1 (hr)
EA (1)	EA001259B1 (hr)
EE (1)	EE03664B1 (hr)
ES (1)	ES2182351T5 (hr)
GB (1)	GB2326334A (hr)
GE (1)	GEP20012462B (hr)
HR (1)	HRP980317B1 (hr)
HU (1)	HU228487B1 (hr)
ID (1)	ID21491A (hr)
IL (1)	IL128484A (hr)
IN (1)	IN189317B (hr)
IS (1)	IS2435B (hr)
IT (1)	IT1293803B1 (hr)
MA (1)	MA26507A1 (hr)
ME (2)	ME00333B (hr)
MY (1)	MY119074A (hr)
NO (1)	NO327775B1 (hr)
NZ (1)	NZ334149A (hr)
PL (1)	PL193721B1 (hr)
PT (1)	PT920302E (hr)
RS (1)	RS51274B (hr)
SA (1)	SA98190821B1 (hr)
SI (1)	SI0920302T2 (hr)
SK (1)	SK284430B6 (hr)
TN (1)	TNSN98087A1 (hr)
TR (1)	TR199900288T1 (hr)
TW (1)	TW555570B (hr)
UA (1)	UA70289C2 (hr)
WO (1)	WO1998056349A1 (hr)
ZA (1)	ZA985136B (hr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9616237D0 (en)	1996-08-01	1996-09-11	Norton Healthcare Ltd	Aerosol formulations
US20010031244A1 (en)	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
DZ2947A1 (fr) *	1998-11-25	2004-03-15	Chiesi Farma Spa	Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) *	1998-11-25	2001-02-23	Chiesi Farma Spa	Formulazioni di aerosol medicinali.
IT1313553B1 (it)	1999-07-23	2002-09-09	Chiesi Farma Spa	Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
DE60031504T2 (de)	1999-09-11	2007-04-05	Glaxo Group Ltd., Greenford	Fluticasonpropionat arzneizubereitung
WO2001037805A1 (en) *	1999-11-23	2001-05-31	Glaxo Group Limited	Pharmaceutical formulations of salmeterol
WO2001047493A1 (en) *	1999-12-24	2001-07-05	Glaxo Group Limited	Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317846B1 (it) *	2000-02-22	2003-07-15	Chiesi Farma Spa	Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) *	2000-05-12	2003-08-27	Chiesi Farma Spa	Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
MXPA02011414A (es)	2000-05-22	2003-06-06	Chiesi Farma Spa	Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis.
WO2002072067A2 (en) *	2001-03-12	2002-09-19	Glaxo Group Limited	Pharmaceutical aerosol formulation
ES2222294T3 (es)	2001-07-02	2005-02-01	Chiesi Farmaceutici S.P.A.	Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP1340503A1 (en) *	2002-03-01	2003-09-03	CHIESI FARMACEUTICI S.p.A.	Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery
RS52387B (sr)	2002-03-01	2013-02-28	Chiesi Farmaceutici S.P.A.	Formoterol najfiniji preparat
EP1340492A1 (en) *	2002-03-01	2003-09-03	CHIESI FARMACEUTICI S.p.A.	Aerosol formulations for pulmonary administration of medicaments having systemic effects
DE10214263A1 (de) *	2002-03-28	2003-10-16	Boehringer Ingelheim Pharma	HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
EP1369113B1 (en) *	2002-06-06	2006-11-22	CHIESI FARMACEUTICI S.p.A.	Solubilisation of drugs in HFA propellant by means of emulsions
AU2003293528A1 (en) *	2003-02-04	2004-09-06	Chrysalis Technologies Incorporated	Perfluorocarbon and hydrofluorocarbon formulations and methods of making and using same
EP1915985A1 (en)	2003-03-20	2008-04-30	Boehringer Ingelheim Pharmaceuticals Inc.	Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants
ME00420B (me) *	2003-03-20	2011-12-20	Boehringer Ingelheim Pharmaceuticals Inc	Formulacija, za inhalator u kojem se odmjerava doza, u kojoj se kao propelenti koriste hidro-fluoro-alkani
SE0303179D0 (sv) *	2003-11-26	2003-11-26	Astrazeneca Ab	Novel compounds
EP1595531A1 (en)	2004-05-13	2005-11-16	CHIESI FARMACEUTICI S.p.A.	Stable pharmaceutical solution formulations for pressurized metered dose inhalers
MXPA06015204A (es)	2004-07-02	2007-03-15	Boehringer Ingelheim Int	Formulaciones en suspension de aerosol con tg 227 ea o tg 134 a como agentes propulsores.
DE102006017320A1 (de)	2006-04-11	2007-10-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
GB0621707D0 (en) *	2006-10-31	2006-12-13	Univ London Pharmacy	Formulations for delivery via pressurised metered dose inhalers
GB0712454D0 (en)	2007-06-27	2007-08-08	Generics Uk Ltd	Pharmaceutical compositions
EP2217278A1 (en) *	2007-11-07	2010-08-18	AstraZeneca AB	Dry powder formulations comprising ascorbic acid derivates
EP2613829B1 (en) *	2010-09-06	2022-06-29	Chiesi Farmaceutici S.p.A.	Metered-dose inhaler
JP5409594B2 (ja) *	2010-12-22	2014-02-05	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	加圧式定量吸入器のための安定な製薬学的溶液製剤
JP6335798B2 (ja)	2012-02-28	2018-05-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規噴射剤含有チオトロピウム製剤
RU2504402C1 (ru) *	2012-11-20	2014-01-20	Шолекс Девелопмент Гмбх	Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких
GB201402513D0 (en)	2014-02-13	2014-04-02	Cardiff Scintigraphics Ltd	Pressurised metered dose inhalers and method of manufacture
US20170189329A1 (en)	2014-07-29	2017-07-06	3M Innovative Properties Company	Method of preparing a pharmaceutical composition
EP3436115B1 (en)	2016-03-31	2021-07-28	Chiesi Farmaceutici S.p.A.	Aerosol inhalation device
GEP20217240B (en) *	2016-09-19	2021-03-25	Mexichem Fluor Sa De Cv	Pharmaceutical composition
WO2025039045A1 (en) *	2023-08-23	2025-02-27	Inhaler Supplies Pty Ltd	Inhalable formulation for volatile actives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1987005211A1 (fr) †	1986-03-10	1987-09-11	Kurt Burghart	Preparation pharmaceutique et son procede de production
ATE60226T1 (de) †	1986-03-10	1991-02-15	Kurt Burghart	Pharmazeutikum sowie verfahren zu seiner herstellung.
US4899874A (en) †	1988-04-26	1990-02-13	Rehrig-Pacific Company, Inc.	Stackable low depth bottle case
US5225183A (en) †	1988-12-06	1993-07-06	Riker Laboratories, Inc.	Medicinal aerosol formulations
GB8828477D0 (en) *	1988-12-06	1989-01-05	Riker Laboratories Inc	Medical aerosol formulations
DE3905726A1 (de) *	1989-02-24	1990-08-30	Hoechst Ag	Druckgaspackung und treibmittel fuer aerosole
AU658854B2 (en) †	1990-10-18	1995-05-04	Minnesota Mining And Manufacturing Company	Aerosol formulation comprising beclomethasone 17,21 dipropionate
GB9024365D0 (en) *	1990-11-09	1991-01-02	Glaxo Group Ltd	Medicaments
EP0504112A3 (en) *	1991-03-14	1993-04-21	Ciba-Geigy Ag	Pharmaceutical aerosol formulations
ATE134509T1 (de) †	1991-06-10	1996-03-15	Schering Corp	Fluorchlorkohlenwasserstoffreie aerosolformulierungen
HUT67445A (en) †	1991-06-10	1995-04-28	Schering Corp	Aerosol formulations containing 1,1,1,2-tetrafluorethane
DE4123663A1 (de) *	1991-07-17	1993-01-21	Schwabe Willmar Gmbh & Co	Aerosol-zubereitung und verwendung eines treibmittels dafuer
DE4123668A1 (de) *	1991-07-17	1993-01-21	Rovema Gmbh	Verfahren und vorrichtung zur zufuehrung von folienmaterial zu einer intermittierend arbeitenden schlauchbeutelmaschine
NZ246046A (en) *	1991-12-12	1995-12-21	Glaxo Group Ltd	Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
ATE204743T1 (de) *	1991-12-18	2001-09-15	Minnesota Mining & Mfg	Aerosolzusammensetzungen für arzneimittelsuspensionen
SG52459A1 (en) *	1992-12-09	1998-09-28	Boehringer Ingelheim Pharma	Stabilized medicinal aerosol solution formulations
US5502076A (en) *	1994-03-08	1996-03-26	Hoffmann-La Roche Inc.	Dispersing agents for use with hydrofluoroalkane propellants
US5508023A (en) *	1994-04-11	1996-04-16	The Center For Innovative Technology	Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US5534242A (en) †	1994-05-02	1996-07-09	Henry; Richard A.	Lidocaine-vasoconstrictor aerosol preparation
CA2189351C (en) †	1994-05-13	2008-12-30	Stephen J. Farr	Narcotic containing aerosol formulation
US5653961A (en) †	1995-03-31	1997-08-05	Minnesota Mining And Manufacturing Company	Butixocort aerosol formulations in hydrofluorocarbon propellant
US5635161A (en) †	1995-06-07	1997-06-03	Abbott Laboratories	Aerosol drug formulations containing vegetable oils
GB9517998D0 (en) †	1995-09-04	1995-11-08	Bioglan Lab Ltd	Compositions and device for their administration
JP2000514085A (ja) *	1996-07-08	2000-10-24	ローヌ―プーラン・ロウラー・リミテッド	医薬シクロスポリンａエーロゾル溶液処方物
DE69734017T2 (de) †	1996-12-04	2006-06-14	Link Products Ltd	Arzneimittelzusammensetzungen und vorrichtungen zu deren verabreichung
US6461591B1 (en) †	1997-02-05	2002-10-08	Jago Research Ag	Medical aerosol formulations

1997
- 1997-06-13 GB GB9712434A patent/GB2326334A/en not_active Withdrawn
- 1997-07-28 IT IT97MI001798A patent/IT1293803B1/it active IP Right Grant
1998
- 1998-06-10 ME MEP-2008-440A patent/ME00333B/me unknown
- 1998-06-10 KR KR1019997001274A patent/KR100546239B1/ko not_active Expired - Lifetime
- 1998-06-10 BR BRPI9805993-9A patent/BR9805993B1/pt active IP Right Grant
- 1998-06-10 HU HU0001339A patent/HU228487B1/hu unknown
- 1998-06-10 ES ES98937474T patent/ES2182351T5/es not_active Expired - Lifetime
- 1998-06-10 SK SK176-99A patent/SK284430B6/sk not_active IP Right Cessation
- 1998-06-10 CA CA002263445A patent/CA2263445C/en not_active Expired - Lifetime
- 1998-06-10 AT AT98937474T patent/ATE222751T1/de active
- 1998-06-10 EA EA199900201A patent/EA001259B1/ru not_active IP Right Cessation
- 1998-06-10 AU AU86262/98A patent/AU729966B2/en not_active Expired
- 1998-06-10 CN CNB988008300A patent/CN1138532C/zh not_active Expired - Lifetime
- 1998-06-10 CZ CZ1999462A patent/CZ295521B6/cs not_active IP Right Cessation
- 1998-06-10 DE DE69807420T patent/DE69807420T3/de not_active Expired - Lifetime
- 1998-06-10 PT PT98937474T patent/PT920302E/pt unknown
- 1998-06-10 SI SI9830245T patent/SI0920302T2/sl unknown
- 1998-06-10 EP EP98937474A patent/EP0920302B2/en not_active Expired - Lifetime
- 1998-06-10 ID IDW990051A patent/ID21491A/id unknown
- 1998-06-10 DK DK98937474T patent/DK0920302T4/da active
- 1998-06-10 IL IL12848498A patent/IL128484A/en not_active IP Right Cessation
- 1998-06-10 JP JP50162299A patent/JP4380802B2/ja not_active Expired - Lifetime
- 1998-06-10 WO PCT/EP1998/003533 patent/WO1998056349A1/en not_active Ceased
- 1998-06-10 RS YUP-69/99A patent/RS51274B/sr unknown
- 1998-06-10 ME MEP-440/08A patent/MEP44008A/hr unknown
- 1998-06-10 EP EP02007496A patent/EP1219293A3/en not_active Withdrawn
- 1998-06-10 TR TR1999/00288T patent/TR199900288T1/xx unknown
- 1998-06-10 PL PL98331531A patent/PL193721B1/pl unknown
- 1998-06-10 NZ NZ334149A patent/NZ334149A/xx not_active IP Right Cessation
- 1998-06-10 GE GEAP19984709A patent/GEP20012462B/en unknown
- 1998-06-10 EE EEP199900055A patent/EE03664B1/xx unknown
- 1998-06-12 CO CO98033837A patent/CO4940408A1/es unknown
- 1998-06-12 AR ARP980102805A patent/AR012977A1/es not_active Application Discontinuation
- 1998-06-12 MA MA25113A patent/MA26507A1/fr unknown
- 1998-06-12 TN TNTNSN98087A patent/TNSN98087A1/fr unknown
- 1998-06-12 ZA ZA985136A patent/ZA985136B/xx unknown
- 1998-06-12 HR HR980317A patent/HRP980317B1/xx not_active IP Right Cessation
- 1998-06-12 MY MYPI98002641A patent/MY119074A/en unknown
- 1998-06-13 DZ DZ980126A patent/DZ2516A1/xx active
- 1998-06-18 IN IN1604DE1998 patent/IN189317B/en unknown
- 1998-07-08 TW TW087111036A patent/TW555570B/zh not_active IP Right Cessation
- 1998-10-06 UA UA99020906A patent/UA70289C2/uk unknown
- 1998-11-25 SA SA98190821A patent/SA98190821B1/ar unknown
1999
- 1999-02-09 NO NO19990594A patent/NO327775B1/no not_active IP Right Cessation
- 1999-02-11 IS IS4974A patent/IS2435B/is unknown
- 1999-03-01 BG BG103221A patent/BG63906B1/bg unknown

Also Published As

Publication number	Publication date
EA001259B1 (ru)	2000-12-25
WO1998056349A1 (en)	1998-12-17
CN1229355A (zh)	1999-09-22
KR100546239B1 (ko)	2006-01-26
EA199900201A1 (ru)	1999-06-24
AU8626298A (en)	1998-12-30
NO327775B1 (no)	2009-09-21
MY119074A (en)	2005-03-31
MA26507A1 (fr)	2004-12-20
BR9805993B1 (pt)	2009-05-05
HU228487B1 (en)	2013-03-28
EE03664B1 (et)	2002-04-15
HUP0001339A3 (en)	2000-10-30
AR012977A1 (es)	2000-11-22
DK0920302T4 (da)	2006-10-09
KR20000068171A (ko)	2000-11-25
SK17699A3 (en)	1999-07-12
UA70289C2 (uk)	2004-10-15
NZ334149A (en)	2000-07-28
ATE222751T1 (de)	2002-09-15
HK1022271A1 (en)	2000-08-04
EP0920302B1 (en)	2002-08-28
EP0920302A1 (en)	1999-06-09
HUP0001339A2 (hu)	2000-09-28
BG103221A (en)	1999-09-30
ES2182351T3 (es)	2003-03-01
DK0920302T3 (da)	2002-12-23
GEP20012462B (en)	2001-06-25
ME00333B (me)	2011-02-10
CO4940408A1 (es)	2000-07-24
DZ2516A1 (fr)	2004-11-08
IS2435B (is)	2008-10-15
SI0920302T2 (sl)	2006-10-31
ID21491A (id)	1999-06-17
ITMI971798A1 (it)	1999-01-28
SK284430B6 (sk)	2005-04-01
CN1138532C (zh)	2004-02-18
EP0920302B2 (en)	2006-06-21
BR9805993A (pt)	1999-08-31
TNSN98087A1 (fr)	2005-03-15
DE69807420T2 (de)	2003-05-08
IS4974A (is)	1999-02-11
EP1219293A3 (en)	2003-05-28
HRP980317A2 (en)	1999-04-30
IN189317B (hr)	2003-02-08
IT1293803B1 (it)	1999-03-10
GB9712434D0 (en)	1997-08-13
ZA985136B (en)	1999-01-07
IL128484A (en)	2004-09-27
EP1219293A2 (en)	2002-07-03
JP2000516965A (ja)	2000-12-19
PT920302E (pt)	2002-11-29
CA2263445A1 (en)	1998-12-17
CZ46299A3 (cs)	1999-07-14
JP4380802B2 (ja)	2009-12-09
PL331531A1 (en)	1999-07-19
CZ295521B6 (cs)	2005-08-17
CA2263445C (en)	2008-09-09
AU729966B2 (en)	2001-02-15
RS51274B (sr)	2010-12-31
ES2182351T5 (es)	2007-03-16
EE9900055A (et)	1999-08-16
DE69807420T3 (de)	2006-11-16
TW555570B (en)	2003-10-01
SA98190821B1 (ar)	2006-11-19
NO990594L (no)	1999-04-13
GB2326334A (en)	1998-12-23
SI0920302T1 (en)	2002-12-31
PL193721B1 (pl)	2007-03-30
MEP44008A (hr)	2011-02-10
TR199900288T1 (xx)	1999-09-21
DE69807420D1 (de)	2002-10-02
HRP980317B1 (en)	2002-06-30
NO990594D0 (no)	1999-02-09
IL128484A0 (en)	2000-01-31
YU6999A (sh)	2000-03-21

Publication	Publication Date	Title
US8420058B2 (en)	2013-04-16	Pharmaceutical aerosol composition
BG63906B1 (bg)	2003-06-30	Фармацевтичен аерозолен състав
CA2352483C (en)	2009-01-20	Pharmaceutical aerosol composition containing hfa 227 and hfa 134a
AU774250B2 (en)	2004-06-24	Pharmaceutical aerosol composition